Prevalence of 25(OH) vitamin D insufficiency and deficiency in chronic kidney disease stage 5 patients on hemodialysis.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a clinical trial.

Little is known about the magnitude of vitamin D deficiency in patients with stage 5 chronic kidney disease (CKD-5) on hemodialysis (HD).

In the present study, the researchers examined the prevalence of vitamin D deficiency in patients with CKD-5 undergoing HD, evaluating the relationship between calcidiol levels with other parameters of mineral metabolism, nutrition/inflammation, functional capacity (FC), and sunlight exposure.

Who Took Part

The abstract describes 84 patients taking part.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

Serum 25(OH) vitamin D levels were evaluated in 84 stable patients on chronic HD not receiving vitamin D supplements, with a mean age 58.9+/-16.6 years, during the month of September (end of winter in the southern hemisphere). 25(OH) vitamin D serum levels, intact PTH (iPTH), as well as serum albumin, calcium, phosphorus, and alkaline phosphatase were analyzed in fasting samples.

What Was Measured

In the present study, the researchers examined the prevalence of vitamin D deficiency in patients with CKD-5 undergoing HD, evaluating the relationship between calcidiol levels with other parameters of mineral metabolism, nutrition/inflammation, functional capacity (FC), and sunlight exposure.

PubMed files the paper under topics including Body Mass Index, Calcifediol, Fasting, Minerals, Practice Guidelines as Topic, Prevalence and Renal Dialysis.

What This Means in Plain Language

This is a clinical trial of Vitamin D, K2, Magnesium and Zinc in 84 patients.

The publication is from 2007 (Hemodialysis international. International Symposium on Home Hemodialysis), a journal based in Canada.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.